Oxaloacetate Pharmacokinetics and Safety

Russell Swerdlow, MD

Status: Completed

Conditions: Alzheimer's Disease

Treatments: Dietary Supplement: Oxaloacetate (OAA)

Study type: Interventional

Funder types: Other

Identifiers

NCT02063308

STUDY00000581

Details and patient eligibility

About

By doing this study, researchers hope to learn how much oxaloacetate (OAA) ends up in the blood after OAA capsules are swallowed, and to assess whether persons with Alzheimer's disease who take OAA for one month have any side-effects.

Enrollment: 6 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Meet criteria for Mild or Moderate AD
• Have a study partner
• Speak English as primary language.

Exclusion criteria

• Absence of a study partner
• Report a potentially confounding, serious medical risk such as type 1 diabetes, cancer, or a recent cardiac event (i.e. heart attack, angioplasty, etc.)

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

6 participants in 1 patient group

Oxaloacetate (OAA)

Experimental group

Description:

100 mg OAA to be taken twice daily over the course of a month

Treatment:

Dietary Supplement: Oxaloacetate (OAA)